Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sodium Fluorescein Clear all

Conditions: Pediatric Neurosurgical Tumors
Interventions: Sodium Fluorescein, Microscopic Resection; Drug · Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 21 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Fundus Photography
Interventions: fundus photography; Device
Lead sponsor: Topcon Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Oakland, New Jersey

Conditions: Vestibular Schwannoma
Interventions: Fluorescein Sodium, YELLOW560 filter; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions: Ozurdex, Bevacizumab; Drug
Lead sponsor: Arman Mashayekhi; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dry Eye Disease
Interventions: In vivo confocal microscopy (IVCM); Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hysterectomy, Cystoscopy
Interventions: water as bladder distending media, intravenous dye, No intervention; Diagnostic Test
Lead sponsor: WellSpan Health; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Extramammary Paget's Disease
Interventions: Fluorescein Sodium; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Ureteral Injury
Interventions: sodium fluorescein, phenazopyridine; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Keratoconus
Interventions: Riboflavin-5-phosphate, Sham cross-linking; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 16 Years to 35 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Amherst, New York • Buffalo, New York

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Meibomian Gland Dysfunction
Interventions: 2-3 Joule LED blue light device; Device
Lead sponsor: Toyos Clinic; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Germantown, Tennessee • Nashville, Tennessee

Conditions: Atrial Septal Defect
Interventions: Fluorescite, Cellvizio 100 Series System with Confocal Miniprobes; Drug · Device
Lead sponsor: Aditya Kaza; Other
Eligibility: 30 Days to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Medical Need for Fluorescein Angiography Imaging
Interventions: Topcon DRI OCT Triton (plus), TRC-50DX retinal camera; Device
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Keratitis
Interventions: B+L Biotrue MPS and B+L PureVision; Device
Lead sponsor: Epstein, Arthur B., OD, FAAO; Individual
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Macular Edema
Interventions: Not listed
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Normal Contact Lens Wear
Interventions: Clear Care, ReNu, OPTI-FREE; Drug
Lead sponsor: Christine Sindt; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Meibomian Gland Dysfunction (MGD)
Interventions: Vevye(Cyclosporine 0.1% Ophthalmic Solution); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Telangiectasia
Interventions: Ranibizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neovascular Age Related Macular Degeneration
Interventions: Physician-guided diagnostic; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more

Conditions: Glaucoma, Glaucoma, Suspect
Interventions: Standard GAT, Fixed force GAT, Upright applanating prototype, Pneumotonometer; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
Interventions: Standing or upright tilt, Microneurography, QSweat, neck cuff stimulation, phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine, clonidine,yohimbine,metoclopramide,alpha-methyldopa, BodPod, Eye exam, Sleep study, Pain response testing, Metabolic chamber, Brain function studies, Bicycle Exercise Test; Procedure · Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 12 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glioblastoma, Glial Tumor, Brain Metastases, Meningioma, Schwannoma, Pituitary Tumor
Interventions: CONVIVO system, Conventional histologic evaluation; Diagnostic Test · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Idiopathic Axonal Polyneuropathy, Abnormal OGTT
Interventions: Optical coherence tomography,Fluorescein angiography; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 50 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Macular Edema Secondary to Retinal Vein Occlusion
Interventions: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein; Drug · Diagnostic Test
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Fullerton, California • Long Beach, California • Mountain View, California + 48 more

Search by objective public record fields.

Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors

NW500 Non-Mydriatic Retinal Camera Clinical Performance Study

Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Ocular Surface Immune Response in Dry Eye Disease

The Use of Dye-less Cystoscopy in Assessing Urinary Tract Integrity During Hysterectomy

A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)

Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency

Treatment of Keratoconus Using Collagen Cross-Linking

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device

Utilization of Confocal Microscopy During Cardiac Surgery

Triton Fundus Autofluorescence and Fluorescein Angiography

Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses

Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment

Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation

NVAMD Satellite Study

Automated Applanation Tonometry - Updated

The Pathophysiology of Orthostatic Hypotension

Evaluation of the CONVIVO System

The Significance of Glucose Intolerance in the Pathogenesis of Idiopathic Axonal Polyneuropathy

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)